

Yosuke Togashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2351381/publications.pdf>

Version: 2024-02-01

41
papers

3,604
citations

361413

20
h-index

345221

36
g-index

41
all docs

41
docs citations

41
times ranked

4888
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulatory T cells in cancer immunosuppression â€” implications for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 356-371.	27.6	872
2	PD-1 ⁺regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9999-10008.	7.1	655
3	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. <i>Nature Immunology</i> , 2020, 21, 1346-1358.	14.5	431
4	Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. <i>Cancer Cell</i> , 2022, 40, 201-218.e9.	16.8	266
5	Blockade of EGFR improves responsiveness to PD-1 blockade in <i>EGFR</i>-mutated nonâ€”small cell lung cancer. <i>Science Immunology</i> , 2020, 5, .	11.9	160
6	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106.		138
7	An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. <i>Immunity</i> , 2020, 53, 187-203.e8.	14.3	119
8	Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. <i>Journal of Experimental Medicine</i> , 2019, 216, 2701-2713.	8.5	82
9	The critical role of CD4+ T cells in PD-1 blockade against MHC-IIâ€”expressing tumors such as classic Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4069-4082.	5.2	76
10	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 4808-4819.	7.0	66
11	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 357-364.	4.1	65
12	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. <i>Science Immunology</i> , 2021, 6, eabc6424.	11.9	64
13	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€”High Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1136-1146.	7.0	62
14	Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2522-2522.	1.6	55
15	Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 3-27.	1.1	48
16	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. <i>Cell Reports</i> , 2022, 38, 110331.	6.4	45
17	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). <i>Clinical Cancer Research</i> , 2020, 26, 5887-5894.	7.0	44
18	Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants. <i>New England Journal of Medicine</i> , 2021, 384, 42-50.	27.0	40

#	ARTICLE	IF	CITATIONS
19	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134.		32
20	Mutational activation of the epidermal growth factor receptor downâ€regulates major histocompatibility complex class I expression via the extracellular signalâ€regulated kinase in nonâ€small cell lung cancer. Cancer Science, 2019, 110, 52-60.	3.9	31
21	Aging, cancer, and antitumor immunity. International Journal of Clinical Oncology, 2022, 27, 316-322.	2.2	29
22	HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability. Gastroenterology, 2022, 162, 799-812.	1.3	28
23	Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251.		26
24	Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. Gastric Cancer, 2020, 23, 893-903.	5.3	20
25	Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. Scientific Reports, 2021, 11, 341.	3.3	17
26	Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. JCI Insight, 2021, 6, .	5.0	17
27	Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Antiâ€PD-1 Therapy. Journal of Investigative Dermatology, 2019, 139, 1490-1496.	0.7	15
28	<scp>HSP90</scp> inhibition overcomes <scp><i>EGFR</i></scp> amplificationâ€induced resistance to thirdâ€generation <scp>EGFRâ€TKIs</scp>. Thoracic Cancer, 2021, 12, 631-642.	1.9	14
29	A variety of â€exhaustedâ€ T cells in the tumor microenvironment. International Immunology, 2022, 34, 563-570.	4.0	13
30	Voltage: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer.. Journal of Clinical Oncology, 2019, 37, 3606-3606.	1.6	12
31	Mechanisms of resistance to immune checkpoint inhibitors. Cancer Science, 2022, 113, 3303-3312.	3.9	12
32	The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. International Immunology, 2020, 32, 273-281.	4.0	10
33	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. Blood Cancer Discovery, 2021, 2, 450-467.	5.0	10
34	Suppression from beyond the grave. Nature Immunology, 2017, 18, 1285-1286.	14.5	10
35	Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. Lung Cancer, 2016, 101, 11-15.	2.0	9
36	Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinoma. Lung Cancer, 2020, 147, 12-20.	2.0	5

#	ARTICLE	IF	CITATIONS
37	TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4141-TPS4141.	1.6	2
38	Programmed Death-Ligand 1â€“Rich Premetastatic Niche in Adjuvant Chemotherapy. Journal of Thoracic Oncology, 2022, 17, 10-12.	1.1	2
39	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications, 2022, 2, 739-753.	1.7	2
40	Regulatory-T cells (Tregs) in tumor infiltrating lymphocytes (TILs) from patients with advanced gastric cancer (AGC) after chemotherapy containing ramucirumab.. Journal of Clinical Oncology, 2017, 35, e15570-e15570.	1.6	0
41	Cancer-immunotherapy biomarkers in the tumor microenvironment. Okayama Igakkai Zasshi, 2021, 133, 151-157.	0.0	0